Platelet-derived miR-92a downregulates cysteine protease inhibitor cystatin C in type II diabetic lower limb ischemia

Zhang,Yunfeng; Guan,Qiang; Jin,Xing

doi:10.3892/etm.2015.2400

Platelet-derived miR-92a downregulates cysteine protease inhibitor cystatin C in type II diabetic lower limb ischemia

Authors:
- Yunfeng Zhang
- Qiang Guan
- Xing Jin
View Affiliations

Affiliations: Department of Vascular Surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Vascular Surgery, Shanxi Province People's Hospital, Taiyuan, Shanxi 030012, P.R. China
Published online on: April 1, 2015 https://doi.org/10.3892/etm.2015.2400
Pages: 2257-2262

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of microRNA (miR)-92a on cystatin C expression in patients with type II diabetes and lower limb ischemia. A total of 199 patients diagnosed with type II diabetes were included in the study and divided into three experimental groups: Simple type II diabetes mellitus (T2DM; n=60) group; type II diabetes with light to moderate occlusion (LLI‑LM; n=70) group; and the type II diabetes with severe occlusion (LLI‑S; n=69) group according to the patient ankle‑brachial index score. In addition, 60 healthy individuals were examined as a control population. The expression levels of various biochemical indices were detected, including cystatin C in the peripheral blood. The expression levels of miR‑92a and cystatin C mRNA were detected by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and the correlation between miR‑92a, cystatin C and the pathological development of type II diabetic lower limb ischemia was analyzed. The protein expression levels of cystatin C were detected using western blot analysis. Bioinformatic analysis indicated that miR‑92a was able to downregulate cystatin C expression, and this result was supported by endothelial cell transfection. In the transfection assay, an miR‑92a mimic downregulated cystatin C expression, while an miR‑92a inhibitor upregulated cystatin C expression. The results of the RT‑qPCR indicated that the expression levels of miR‑92a in the LLI‑S group were reduced compared with those in the T2DM and LLI‑LM groups, and significantly lower compared with those in the negative control group. Platelet‑derived miR‑92a appeared to downregulate cystatin C expression in patients with type II diabetes and lower limb ischemia. Therefore, the combined detection of miR‑92a and cystatin C may be useful as a method for clinically screening patients with type II diabetes for lower limb ischemia.

View Figures

View References

1	Ouriel K: Peripheral arterial disease. Lancet. 358:1257–1264. 2001. View Article : Google Scholar : PubMed/NCBI
2	Beckman JA, Creager MA and Libby P: Diabetes and atherosclerosis: Epidemiology, pathophysiology and management. JAMA. 287:2570–2581. 2002. View Article : Google Scholar : PubMed/NCBI
3	Ridker PM, Cushman M, Stampfer MJ, Tracy RP and Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 97:425–428. 1998. View Article : Google Scholar : PubMed/NCBI
4	Arain FA and Cooper Jr LT: Peripheral arterial disease: Diagnosis and management. Mayo Clin Proc. 83:944–949. 2008. View Article : Google Scholar : PubMed/NCBI
5	Abrahamson M, Olafsson I, Palsdottir A, Ulvsbäck M, Lundwall A, Jensson O and Grubb A: Structure and expression of the human cystatin C gene. Biochem J. 268:287–294. 1990.PubMed/NCBI
6	Koenig W, Twardella D, Brenner H and Rothenbacher D: Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem. 5l:321–327. 2005. View Article : Google Scholar
7	Watanabe S, Okura T, Liu J, Miyoshi K, et al: Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 26:895–899. 2003. View Article : Google Scholar : PubMed/NCBI
8	Arpegård J, Ostergren J, de Faire U, Hansson LO and Svensson P: Cystatin C - A marker of peripheral atherosclerotic disease? Atherosclerosis. 199:397–401. 2008. View Article : Google Scholar : PubMed/NCBI
9	de Groot M, Anderson R, Freedland KE, Clouse RE and Lustman PJ: Association of depression and diabetes complications: A meta-analysis. Psychosom Med. 63:619–630. 2001. View Article : Google Scholar : PubMed/NCBI
10	Liu F, Shen J, Zhao J, et al: Cystatin C: A strong marker for lower limb ischemia in Chinese type 2 diabetic patients? PloS One. 8:e669072013. View Article : Google Scholar : PubMed/NCBI
11	Berezikov E, Cuppen E and Plasterk RH: Approaches to microRNA discovery. Nat Genet. 38:(Suppl). S2–S7. 2006. View Article : Google Scholar : PubMed/NCBI
12	Stuwe E, Tóth KF and Aravin AA: Small but sturdy: Small RNAs in cellular memory and epigenetics. Genes Dev. 28:423–431. 2014. View Article : Google Scholar : PubMed/NCBI
13	Liu D, Tao T, Xu B, et al: MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6 (STAT6). Biochem Biophys Res Commun. 445:151–156. 2014. View Article : Google Scholar : PubMed/NCBI
14	Loyer X, Potteaux S, Vion AC, et al: Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. 114:434–443. 2014. View Article : Google Scholar : PubMed/NCBI
15	Sun X, Belkin N and Feinberg MW: Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep. 15:3722013. View Article : Google Scholar : PubMed/NCBI
16	Vickers KC, Rye KA and Tabet F: MicroRNAs in the onset and development of cardiovascular disease. Clin Sci (Lond). 126:183–194. 2014. View Article : Google Scholar : PubMed/NCBI
17	Creemers EE, Tijsen AJ and Pinto YM: Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 110:483–495. 2012. View Article : Google Scholar : PubMed/NCBI
18	Huo Y, Schober A, Forlow SB, et al: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 9:61–67. 2003. View Article : Google Scholar : PubMed/NCBI
19	Wilcox JN, Smith KM, Williams LT, Schwartz SM and Gordon D: Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest. 82:1134–1143. 1988. View Article : Google Scholar : PubMed/NCBI
20	Huo Y and Ley KF: Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med. 14:18–22. 2004. View Article : Google Scholar : PubMed/NCBI
21	Nomura S, Suzuki M, Katsura K, et al: Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis. 116:235–240. 1995. View Article : Google Scholar : PubMed/NCBI
22	Shi GP, Sukhova GK, Grubb A, et al: Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 104:1191–1197. 1999. View Article : Google Scholar : PubMed/NCBI
23	Taglieri N, Koenig W and Kaski JC: Cystatin C and cardiovascular risk. Clin Chem. 55:1932–1943. 2009. View Article : Google Scholar : PubMed/NCBI
24	Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K and Higaki J: Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 26:895–899. 2003. View Article : Google Scholar : PubMed/NCBI